In the News

Prothena and Roche moving ahead with alpha-synuclein-targeting drug for Parkinson’s disease

By October 27, 2020 January 4th, 2021 No Comments

Prothena and Roche moving ahead with alpha-synuclein-targeting drug for Parkinson’s disease  

Good news in the world of drug development and future treatments for synucleinopathies: Based on positive results from the PASADENA trial, which examined the safety and efficacy of prasinezumab in early Parkinson’s disease, Prothena and Roche announced that they will move the anti-alpha-synuclein antibody into a Phase 2b study.

Currently available treatments for Parkinson’s disease focus on controlling symptoms, however, prasinezumab targets the underlying cause–the accumulation of the protein alpha-synuclein. It is the first alpha-synuclein antibody to move into a late-stage clinical trial.

READ THE PRESS RELEASE